Abstract Body

Background: Recent data have suggested that concentrations of raltegravir (RAL) in gut tissue are high after oral administration to humans, with implications for treatment and prevention. We have used in silico, in vitro, ex vivo and in vivo models to further investigate the accumulation of RAL in gut tissue. Methodology: Gut-to-plasma affinity was predicted in silico for RAL and lopinavir (LPV) using the Poulin Theil equation. Cellular accumulation of RAL and LPV (both 1 μM) was determined at pH 5, 6, 7 and 8 in Caco-2 gut epithelial cells (15×106 cells, 37°C, 30 min). Gut-associated concentrations were determined ex vivo after incubation of 100g rat small intestine (SI) or large intestine (LI) with human plasma (3 mL, 37°C, 4 hours) containing RAL and LPV (both 50 μM). Finally, RAL concentrations in plasma, gut contents, SI and LI were determined after oral dosing (8 mg/kg) to Wistar rats with 1 and 4 hour post-dose blood/tissue sampling. In vivo samples were analysed using LC-MS/MS and other samples were analysed using scintillation counting (3H RAL and 3H LPV). Results: Gut-to-plasma affinity ratios for RAL and LPV were predicted to be 0.53 and 6.38 in silico, respectively. Intracellular RAL in Caco-2 cells ranged from 1.41 μM (pH 5) to 0.42 μM (pH 8) and LPV ranged from 24.8 μM (pH 5) to 27.5 μM (pH 8). In ex vivo studies, RAL accumulated less than LPV in both SI (29.6 versus 65.7 μM, p < 0.05) and LI (34.9 versus 53.5 μM, p < 0.05). After oral administration to rats, RAL concentrations decreased in plasma between 1hr (0.63 } 0.13 μM) and 4hr post-dose (0.05 } 0.03 μM, p < 0.05) and in SI (1.4 } 0.26 μM to 0.47 } 0.27 μM, p < 0.05) but did not change in SI contents (5.2 } 3.8 μM to 4.0 } 3.2 μM, p = 0.72). Conversely, increases in LI (0.38 } 0.15 μM to 1.36 } 0.50 μM, p < 0.05) and LI contents (0.15 } 0.09 μM to 40.6 } 3.3 μM, p < 0.05) were observed (Figure). Conclusions: RAL accumulated highly in gut tissue in vivo but this was not observed ex vivo or in vitro, indicating that high tissue-associated RAL concentrations in vivo were not driven by plasma-to-tissue accumulation but by high RAL concentrations in gut contents. However, given that intracellular penetration is a prerequisite for RAL activity, further study is required to preclude artefacts that may arise from contamination with gut contents. The gut is a relevant site for both pre-exposure prophylaxis (PrEP) and HIV eradication, and this screening system can be used to select for drugs with preferential accumulation in gut tissue.